dc.contributor.author | López-Villar, Elena | |
dc.contributor.author | Martos Moreno, Gabriel Ángel | |
dc.contributor.author | Chowen, Julie Ann | |
dc.contributor.author | Okada, Shigeru | |
dc.contributor.author | Kopchick, John J. | |
dc.contributor.author | Argente Oliver, Jesús | |
dc.contributor.other | UAM. Departamento de Pediatría | es_ES |
dc.contributor.other | Instituto de Investigación del Hospital de La Princesa (IP) | es_ES |
dc.date.accessioned | 2016-07-28T13:39:11Z | |
dc.date.available | 2016-07-28T13:39:11Z | |
dc.date.issued | 2015-01-01 | |
dc.identifier.citation | Journal of Cellular and Molecular Medicine 19.7 (2015): 1455-1470 | en_US |
dc.identifier.issn | 1582-1838 | es_ES |
dc.identifier.issn | 1582-4934 (on line) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/672290 | |
dc.description.abstract | The incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However,
the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceutical
communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in
proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification
of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that
have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new
strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel
therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes area | en_US |
dc.description.sponsorship | This work is funded by Ministerio de Ciencia e Innovación (BFU2011–27492),
Fondos de Investigación Sanitaria (PI1302195), Centro de Investigación
Biomédica en Red Fisiopatología de Obesidad y Nutrición (CIBERobn), Instituto
de Salud Carlos III and Fundación de Endocrinología y Nutrición. Dr. Elena
López Villar is supported by ISCIII Spanish Health System (SNS BOE 2012)
and she is Delegate of HUPO (Human Proteome Organization) supporting clinical
proteomic studies at Hospital Niño Jesús of Madrid, Spain, to improve
diagnosis and therapies via research | en_US |
dc.format.extent | 16 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | John Wiley & Sons Ltd. | en_US |
dc.publisher | Foundation for Cellular and Molecular Medicine | en_US |
dc.relation.ispartof | Journal of Cellular and Molecular Medicine | en_US |
dc.rights | © 2015 The Authors | en_US |
dc.subject.other | Biomarkers | en_US |
dc.subject.other | Diabetes mellitus type 2 | en_US |
dc.subject.other | Obesity | en_US |
dc.subject.other | Proteomics | en_US |
dc.title | A proteomic approach to obesity and type 2 diabetes | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1111/jcmm.12600 | es_ES |
dc.identifier.doi | 10.1111/jcmm.12600 | es_ES |
dc.identifier.publicationfirstpage | 1455 | es_ES |
dc.identifier.publicationissue | 7 | es_ES |
dc.identifier.publicationlastpage | 1470 | es_ES |
dc.identifier.publicationvolume | 19 | es_ES |
dc.relation.projectID | Gobierno de España. BFU2011–27492 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Argente Oliver, Jesús (100008) | |
dc.authorUAM | Chowen , Julie Ann (268961) | |
dc.authorUAM | Martos Moreno, Gabriel Ángel (101491) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa) | |